NYSE:DNA | Free Cash Flow | Ginkgo Bioworks Holdings, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$46.69M$1.93M-$48.62M
2025-12-31-$47.68M$5,000.00-$47.68M
2025-03-31-$51.52M$7.62M-$59.14M
2024-12-31-$42.44M$13.71M-$56.15M
2024-03-31-$89.26M$6.71M-$95.97M
2023-12-31-$57.83M$3.45M-$61.28M
2023-03-31-$90.59M$19.44M-$110.03M
2022-12-31-$104.53M$25.65M-$130.18M
2022-03-31-$19.9M$3.58M-$23.48M
2021-12-31-$165.54M$5.11M-$170.66M
2021-03-31-$48.13M$21.94M-$70.07M
2020-12-31-$59.34M$19.41M-$78.75M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$171.06M$7.67M-$178.72M
2024-12-31-$319.59M$62.54M-$382.13M
2023-12-31-$295.5M$40.8M-$336.3M
2022-12-31-$252.2M$52.27M-$304.47M
2021-12-31-$253.82M$56.52M-$310.34M
2020-12-31-$135.83M$57.82M-$193.65M
2019-12-31-$44.66M$22.22M-$66.88M